Acesso da população brasileira adulta a medicamentos prescritos / Access to prescribed medicine in the Brazilian adult population

RESUMO: Objetivo: Estimar a prevalência e verificar os fatores associados ao acesso a medicamentos prescritos, pela população adulta brasileira, e descrever as distribuições de dispêndio monetário para acesso aos fármacos, fonte de obtenção e motivos para o não acesso. Métodos: Com base em um delineamento transversal, a partir dos dados da Pesquisa Nacional de Saúde de 2013, analisou-se uma amostra composta por indivíduos adultos que tiveram medicamentos prescritos por profissional de saúde, nas duas semanas anteriores à realização da pesquisa. A variável dependente foi o acesso a medicamentos prescritos (total, parcial, nulo). Os dados foram analisados por meio de regressão logística multinomial, considerando-se o acesso total como categoria de referência. Resultados: Os resultados mostraram alta prevalência de acesso total a medicamentos prescritos no Brasil (83,0%; IC95% 81,3 - 84,6). A maioria dos indivíduos teve dispêndio monetário com a obtenção dos fármacos (63,9%), sendo que os principais motivos para o não acesso foram a ausência do medicamento no serviço público de saúde (57,6%) e falta de dinheiro (11,9%). Foram observadas maiores chances de acesso parcial para os indivíduos atendidos no serviço público (OR = 2,5; IC95% 1,58 - 3,97). Maior chance de acesso nulo foi associada à cor de pele não branca (OR = 1,43; IC95% 1,03 - 1,99). Conclusão: Os resultados revelaram iniquidade no acesso a medicamentos, reforçando a necessidade de fortalecimento do Sistema Único de Saúde para o fornecimento gratuito de fármacos, de modo a reduzir as desigualdades.

ABSTRACT: Objective: To estimate the prevalence and check the factors associated with access to prescribed medicine by the Brazilian adult population; and to describe the distribution of the presence of monetary expenditure for the purchase, source of medicines, and the reasons for non-access. Methods: Based on a cross-sectional design, from the 2013 National Health Research data, we analyzed a representative sample of the population that comprised adults with prescriptions written by a health professional, in the two weeks prior to the survey. The dependent variable was the access to prescribed medicines (full access, partial access, no access). Data were analyzed using the multinomial logistic regression considering total access as the reference category. Results: The results showed high prevalence of full access to prescribed medicine in Brazil (83.0%; 95%CI 81.3 - 84.6). Most of the individuals had monetary expenditure on the purchase of medicines (63.9%), and the main reasons for no access were the lack of medicine in the public health service (57.6%) and having no money (11.9%). We found higher chances of partial access among individuals attending the public service (OR = 2.5; 95%CI 1.58 - 3.97). Greater chance of no access was associated with non-white skin color (OR = 1.43; 95%CI 1.03 - 1.99). Conclusion: The results revealed significant inequity in access to medicine, emphasizing the need to strengthen the Unified Health System for the free supply of medicines in order to reduce inequalities.

Factors Contributing to Increases in Prescription Drug Expenditures Borne by National Health Insurance in South Korea

PURPOSE: Rapid growth of prescription drug expenditures is a problem in South Korea. The objective of this study was to assess the contributions of four variables (therapeutic choice, drug-mix, original use, and price changes) to increases in drug expenditures paid by the National Health Insurance (NHI) in Korea. MATERIALS AND METHODS: A retrospective cohort study was conducted between January 1, 2008 and June 30, 2012 utilizing data from the NHI Claims Database of the Health Insurance Review and Assessment Service. The number of target drug types for final analysis was 13959. To analyze the growth rates of drug expenditures, this study used Fisher ideal index and the Laspeyres and Paasche indexes. RESULTS: With the exception of 2012, therapeutic choice contributed to about 40-60% of the increase in drug expenditures every year, while drug-mix contributed to another 30-40%. CONCLUSION: The rapid growth in prescription drug expenditure was found to be largely due to drug-mix and therapeutic choice over time. Original use had little impact on drug spending.

The influence of health expenditures on household impoverishment in Brazil / Influência dos gastos em saúde no empobrecimento de domicílios no Brasil

OBJECTIVE To analyze the variation in the proportion of households living below the poverty line in Brazil and the factors associated with their impoverishment. METHODS Income and expenditure data from the Household Budget Survey, which was conducted in Brazil between 2002-2003 (n = 48,470 households) and 2008-2009 (n = 55,970 households) with a national sample, were analyzed. Two cutoff points were used to define poverty. The first cutoff is a per capita monthly income below R$100.00 in 2002-2003 and R$140.00 in 2008-2009, as recommended by the Bolsa Família Program. The second, which is proposed by the World Bank and is adjusted for purchasing power parity, defines poverty as per capita income below US$2.34 and US$3.54 per day in 2002-2003 and 2008-2009, respectively. Logistic regression was used to identify the sociodemographic factors associated with the impoverishment of households. RESULTS After subtracting health expenditures, there was an increase in households living below the poverty line in Brazil. Using the World Bank poverty line, the increase in 2002-2003 and 2008-2009 was 2.6 percentage points (6.8%) and 2.3 percentage points (11.6%), respectively. Using the Bolsa Família Program poverty line, the increase was 1.6 (11.9%) and 1.3 (17.3%) percentage points, respectively. Expenditure on prescription drugs primarily contributed to the increase in poor households. According to the World Bank poverty line, the factors associated with impoverishment include a worse-off financial situation, a household headed by an individual with low education, the presence of children, and the absence of older adults. Using the Bolsa Família Program poverty line, the factors associated with impoverishment include a worse-off financial situation and the presence of children. CONCLUSIONS Health expenditures play an important role in the impoverishment of segments of the Brazilian population, especially among the most disadvantaged. .

OBJETIVO Analisar a variação na proporção de domicílios vivendo abaixo da linha de pobreza no Brasil e os fatores associados ao empobrecimento. MÉTODOS Foram analisados os dados de despesa e renda das Pesquisas de Orçamentos Familiares conduzidas no Brasil em 2002-2003 (n = 48.470 domicílios) e 2008-2009 (n = 55.970 domicílios) com amostra representativa nacional. Foram utilizados dois pontos de corte para definir pobreza. O primeiro, recomendado pelo Programa Bolsa-Família, considerou pobreza rendimento per capita mensal inferior a R$100,00 em 2002-2003 e a R$140,00 em 2008-2009. O segundo, proposto pelo Banco Mundial, incorpora a correção pela paridade do poder de compra, resultando em US$2,34 por dia, em 2002-2003, e US$3,54, em 2008-2009. Para identificar os fatores sociodemográficos associados ao empobrecimento dos domicílios foi utilizada regressão logística. RESULTADOS Houve acréscimo de domicílios vivendo abaixo da linha de pobreza no Brasil após subtração dos gastos em saúde. Considerando-se a linha de pobreza recomendada pelo Banco Mundial, em 2002-2003 o acréscimo foi 2,6 pontos percentuais (ou 6,8%) e, em 2008-2009, 2,3 pontos percentuais (ou 11,6%). Considerando-se a linha de pobreza utilizada pelo Programa Bolsa-Família, a variação foi 1,6 (11,9%) e 1,3 (17,3%), respectivamente. Gastos com medicamentos foram os que mais contribuíram para o aumento de domicílios pobres. Os fatores associados ao empobrecimento, segundo a linha de pobreza do Banco Mundial, foram apresentar pior situação econômica, ser chefiado por indivíduo com baixa escolaridade, presença de crianças e ausência de idosos. Utilizando-se a linha de pobreza do Bolsa-Família, os fatores associados foram apresentar pior situação econômica e presença de crianças. ...

Relationship between functional fitness, medication costs and mood in elderly people / Relações entre aptidão física funcional, custos com consumo de medicamentos e estados de humor em pessoas idosas

Objective: to verify if functional fitness (FF) is associated with the annual cost of medication consumption and mood states (MSt) in elderly people. Methods: a cross-sectional study with 229 elderly people aged 65 years or more at Santa Casa de Misericórdia de Coimbra, Portugal. Seniors with physical and psychological limitations were excluded, as well as those using medication that limits performance on the tests. The Senior Fitness Test was used to evaluate FF, and the Profile of Mood States - Short Form to evaluate the MSt. The statistical analysis was based on Mancova, with adjustment for age, for comparison between men and women, and adjustment for sex, for comparison between cardiorespiratory fitness quintiles. The association between the variables under study was made with partial correlation, controlling for the effects of age, sex and body mass index. Results: an inverse correlation between cardiorespiratory fitness and the annual cost of medication consumption was found (p < 0.01). FF is also inversely associated with MSt (p < 0.05). Comparisons between cardiorespiratory fitness quintiles showed higher medication consumption costs in seniors with lower aerobic endurance, as well as higher deterioration in MSt (p < 0.01). Conclusion: elderly people with better FF and, specifically, better cardiorespiratory fitness present lower medication consumption costs and a more positive MSt. .

Objetivo: verificar se a aptidão física funcional (AFF) tem associação com o custo anual de consumo de medicamentos e com os estados de humor (EH) em pessoas idosas. Métodos: estudo transversal com 229 idosos de 65 anos de idade ou mais da Instituição Santa Casa de Misericórdia de Coimbra, Portugal. Foram excluídos os idosos com limitações físicas e psicológicas e os que usavam medicamentos que condicionariam a realização dos testes. Foram utilizados a bateria Senior Fitness Test e o questionário Profile of Mood States - Short Form como instrumentos de coleta de dados. A análise estatística recorreu à Mancova, com ajuste de idade, para comparação entre homens e mulheres, e ajustada também para o sexo, para comparação entre quintis da aptidão cardiorrespiratória. A associação entre as variáveis de interesse foi feita com a correlação parcial, corrigindo o efeito da idade, do sexo e do índice de massa corpórea. Resultados: verificou-se a existência de correlação inversa entre a aptidão cardiorrespiratória e o custo anual de consumo de medicamentos (p < 0,01). A AFF associou-se também inversamente com os EH (p < 0,05). As comparações entre os quintis da aptidão cardiorrespiratória revelaram maior consumo de medicamentos em idosos com menor resistência aeróbia, assim como maior deterioração dos EH (p < 0,01). Conclusão: idosos com melhor AFF e, particularmente, melhor aptidão cardiorrespiratória apresentam menores custos com consumo de medicamentos e EH mais positivos. .

Evolución del consumo de medicamentos de alto costo en Colombia / Evolution of consumption of high-cost drugs in Colombia

Objective. Determine the patterns of consumption of high-cost drugs (HCD) during the 2005–2010 period in a population of Colombian patients enrolled in the General System of Social Security in Health. Methods. An observational descriptive study was conducted. The prescription dataof formulas of any drug considered to be high-cost dispensed to all users (1 674 517) in 20 cities of Colombia between 2005 and 2010 were analyzed. The anatomical therapeutic classification was considered, and the number of patients as well as monthly invoicing for each drug, the daily dose defined, and the cost per 1 000 inhabitants/day were defined. Results. Over the entire study period, the amount invoiced for HCDs increased by 847.4%. Antineoplastic and immunomodulator drugs accounted for 46.3% of the totalinvoicing. The other drugs were anti-infectives (15.2%), systemic hormonal preparations (9.5%), and drugs for the nervous system (9.1%). Most of these drugs were prescribed at the daily doses defined as recommended by the World Health Organization, but with high costs per 1 000 inhabitants/day. Conclusions. In Colombia a crisis has occurred in recent years due to the high spending generated by the most expensive drugs. The progressive growth of pharmaceutical spending is greater than the increased coverage by the country’s health system. The Colombian health system should evaluate how much it is willing to pay for the most expensive drugs for some diseases and what strategies should be implemented to cover these expenses and thus guarantee access to the insured.

Objetivo. Determinar el comportamiento del consumo de medicamentos de alto costo (MAC) durante 2005–2010 en una población de pacientes colombianos afiliados al Sistema General de Seguridad Social en Salud. Métodos. Estudio descriptivo observacional; se analizaron datos de prescripción de fórmulas dispensadas desde 2005 a 2010 a todos los usuarios (1 674 517) de algún medicamento considerado de alto costo en 20 ciudades de Colombia. Se consideró la clasificación anatómicaterapéutica y el número de pacientes, así como la facturación mensual por cada medicamento, la dosis diaria definida y el costo por 1 000 habitantes/día. Resultados. En todo el período de estudio, el valor facturado por MAC creció 847,4%. Losantineoplásicos e inmunomoduladores constituyeron 46,3% del total facturado, antinfecciosos 15,2%, preparaciones hormonales sistémicas 9,5% y fármacos para el sistema nervioso 9,1%. La mayoría de estos medicamentos fueron prescritos a las dosis diarias definidas recomendadaspor la Organización Mundial de Salud, pero con altos costos por 1 000 habitantes y día. Conclusiones. En Colombia durante los últimos años se ha presentado una crisis debida al elevado gasto generado por los medicamentos más costosos. El crecimiento progresivo del gasto farmacéutico es mayor que el aumento de la cobertura del sistema sanitario del país. El sistema sanitario colombiano debe evaluar cuánto está dispuesto a pagar por los medicamentosmás costosos para algunas morbilidades y qué estrategias debe implementar para sufragar estos gastos y así garantizar el acceso a los asegurados.

Capacidade aquisitiva e disponibilidade de medicamentos para doenças crônicas no setor público / Affordability and availability of drugs for treatment of chronic diseases in the public health care system

OBJETIVO: Avaliar a capacidade aquisitiva do trabalhador para pagar medicamentos utilizados no tratamento de doenças crônicas e a disponibilidade desses medicamentos na forma de referência, similar ou genérica para fornecimento gratuito no setor público. MÉTODOS: Utilizou-se metodologia preconizada pela Organização Mundial da Saúde (OMS) e Health Action International (HAI) para coleta padronizada de informações sobre preços de venda no setor privado e disponibilidade no setor público de medicamentos em seis cidades do Rio Grande do Sul, Brasil. A coleta de dados ocorreu de novembro de 2008 a janeiro de 2009. A capacidade aquisitiva foi estimada como o número de dias do salário que um trabalhador com rendimento de 1 salário mínimo nacional necessita trabalhar para adquirir, em uma farmácia privada, a quantidade necessária de medicamento para 1 mês de tratamento. A disponibilidade foi avaliada verificando-se a presença dos medicamentos nas farmácias do setor público. RESULTADOS: A pesquisa incluiu 22 estabelecimentos públicos e 30 farmácias privadas. Dos 21 medicamentos utilizados no tratamento de sete doenças crônicas, apenas nove eram disponibilizados gratuitamente nos seis municípios pesquisados. O percentual médio da disponibilidade variou de 83,3 por cento (São Leopoldo) a 97,6 por cento (Caxias do Sul). A capacidade aquisitiva variou de 0,4 a 10,5 dias de salário para medicamentos de referência; de 0,2 a 8,4 dias de salário para medicamentos similares; e de 0,3 a 3,8 dias de salário para medicamentos genéricos. CONCLUSÕES: A disponibilidade geral dos medicamentos pesquisados foi superior aos 80 por cento recomendados pela OMS; porém, alguns tratamentos não estavam disponíveis, ou apresentaram uma disponibilidade limitada no setor público. A capacidade aquisitiva dos trabalhadores nos municípios estudados indicou um comprometimento de dias do salário que pode afetar a continuidade dos tratamentos com medicamentos para doenças crônicas.

OBJECTIVE: To assess the affordability by workers of drugs used for treatment of chronic diseases, as well as the availability of the reference, similar, or generic forms of these drugs in the public health care system. METHODS: We employed the methodology recommended by the World Health Organization (WHO) and Health Action International (HAI) for the standardized collection of information on selling prices in the private sector and availability in the public health care system of drugs in six cities in the state of Rio Grande do Sul, Brazil. Data were collected from November 2008 to January 2009. Affordability was estimated as the number of salary days required for a worker receiving the national minimum wage to buy, in a private pharmacy, the amount of medication required for one month of treatment. Availability was assessed by the presence of these drugs in public health care system facilities. RESULTS: Twenty-two public facilities and 30 private pharmacies were studied. Of 21 drugs used for the treatment of seven chronic disorders, only nine were available free of charge in the six cities. Mean availability ranged from 83.3 percent (São Leopoldo) to 97.6 percent (Caxias do Sul). Affordability ranged from 0.4 to 10.5 salary days for reference drugs, 0.2 to 8.4 salary days for similar drugs, and 0.3 to 3.8 salary days for generic drugs. CONCLUSIONS: The overall availability of the drugs surveyed was higher than the 80 percent recommended by WHO. However, some treatments were not available, or had limited availability in the public system. Concerning affordability, the number of salary days required to buy these drugs may affect the continuation of drug treatments for chronic diseases.

Abasto, surtimiento y gasto de bolsillo en medicamentos en hospitales públicos de México en 2009 / Supply prescription filling and out-of-pocket expenditures on medicines in public hospitals in Mexico in 2009

OBJETIVO. Analizar la disponibilidad de medicamentos en las farmacias hospitalarias, el surtimiento de prescripciones a pacientes egresados y el gasto de bolsillo en medicamentos de pacientes hospitalizados. MATERIAL Y MÉTODOS. Análisis descriptivo de la Encuesta Nacional de Satisfacción y Trato Adecuado (ENSATA) de 2009 con una muestra representativa de hospitales públicos sobre disponibilidad de una lista de 83 medicamentos en el momento de la visita a la farmacia, la proporción del surtimiento de recetas a pacientes en el momento de su alta y su gasto de bolsillo durante su estancia hospitalaria. RESULTADOS. En total se entrevistó a 26 271 pacientes egresados de los 160 hospitales públicos visitados. La disponibilidad de medicamentos en el ámbito nacional fue de 82 por ciento. Los hospitales de los Servicios Estatales de Salud (SESA) mostraron una disponibilidad de 77 por ciento (variación de 30 a 96 por ciento). El surtimiento completo de recetas fue de 97 por ciento en las instituciones de seguridad social, cifra que contrasta con 56.2 por ciento de los hospitales de los SESA, que además presentaron una gran varianza entre estados (13 a 94 por ciento) La mediana del gasto de pacientes hospitalizados fue de 150 pesos moneda nacional (1 por ciento gastó más de 10 000 pesos. CONCLUSIONES. La falta de los medicamentos en los hospitales tiene un impacto económico en el gasto de los hogares, particularmente en aquellos que cuentan con pocos recursos, y puede aumentar la morbilidad o mortalidad de los pacientes hospitalizados en las instituciones públicas.

OBJECTIVE. To analyze the availability of drugs in public hospitals, the prescription-filling patterns for in-patients when they are discharged and their out-of-pocket expenditure during their hospitalization. MATERIAL AND METHODS. Using the National Satisfaction and Responsiveness Survey (ENSATA) 2009, which includes a representative sample of public hospitals in Mexico in 2009, the availability of 83 essential medicines in the hospital pharmacies at the day of visit, the proportion of prescriptions completely filled for patients when they are discharged and their out-of-pocket expenditure during their hospitalization were analyzed. RESULTS. A total of 26 271 patients in 160 public hospitals were interviewed. The mean availability of drugs was 82 percent for all hospitals, with the lowest availability for the Ministry of Health (SESA) hospitals (77 percent, with a range of 30 to 96 percent). Patients discharged at social security hospitals received in 97 percent of cases a complete prescription filling, while in SESA hospitals the average was only 56.2 percent, with a large variance among states (13 to 94 percent). The median inpatient spending was 150 pesos in national currency (1 percent spent over 10 000 pesos). CONCLUSIONS. The lack of medicines in public hospitals may increase in-patient morbidity and mortality and has an economic impact on household spending, particularly in those with scarce resources.

Politica y gestion de la cobertura de medicamentos de alto costo: relevamiento de la experiencia internacional y respuesta del Fondo Nacional de Recursos / Policy and management of high-cost drug coverage: survey of the international experience and response of the National Resources Fund

El problema del acceso a los medicamentos, y en particular su impacto creciente sobre las finanzas de los sistemas de salud, se ubica entre los de alta prioridad en buena parte de los países del mundo. A una situación de inequidad que ya existía, se suma hoy en día la irrupción de una nueva generación de medicamentos con una efectividad que todavía es objeto de debate y cuyo elevadísimo costo es una amenaza grave para la estabilidad de los sistemas y la sustentabilidad de las políticas. Además de compartir la situación de la mayor parte de los sistemas del mundo, Uruguay tiene algunas características adicionales. En primer término, existe un elevado nivel de cobertura del sistema de salud con tasas de uso de los servicios mayores a las que suelen encontrarse en países de ingresos medios. Al mismo tiempo, el nivel educativo y el acceso a la información son altos en el Uruguay; se trata de una sociedad bastante medicalizada y el contexto cultural tiende a ver en las organizaciones públicas o estatales una garantía de acceso a prestaciones casi ilimitadas. A lo mencionado se agrega que existe un sistema por el cual la incorporación de un nuevo tratamiento o tecnología, significa su rápida universalización. Ya sea porque se define su obligatoriedad para los prestadores o porque se incluye en el Fondo Nacional de Recursos (FNR), la población accede rápidamente y con mínimas restricciones a estos tratamientos en forma universal. En efecto, el sistema de salud en Uruguay es un modelo garantista de derechos. Esta característica que constituye una notoria fortaleza del sistema en términos éticos, sanitarios y como valor social, obliga a evaluar más cuidadosamente la sustentabilidad de cualquier decisión que se adopte en temas de cobertura de salud de salud ya que fácilmente pueden volverse insostenibles en el tiempo. El tema plantea por lo tanto un doble desafío: sólo se deben incorporar tratamientos y tecnologías que cuenten con evidencia que los respalde y al mismo tiempo se debe contar con un sistema de gestión suficientemente sólido para asegurar que su uso se realice sólo ajustado a la evidencia.

The Contributing Factors to Surplus Medicine by Long-Term Users of Medical Aid in Korea / 예방의학회지

OBJECTIVES: The amount of medical utilization by Medical Aid recipients was 3.7 times that of patients with Korean Medical Insurance. This study aims to describe the surplus medicine and the medication-related utilization, and to determine factors contributing to surplus medicine. METHODS: Among those who used copayment-free Class I Medical Aid in 2005, 146,880 subjects who were > or =19 year-old and received >365 days medical treatment per year were studied with their case managers by conducting face-to-face interviews. The analytic methods were description, chi-square, t-tests, ANCOVA and multiple logistic regressions. RESULTS: Most subjects were female (68.6%), the elderly (62.5%), and the separated (61.6%), had an elementary graduation or less (74.8%), and had disabilities (33.2%). The percentage of subjects with surplus medicine was 18.5%. However, the percentage of females, the elderly, those with non-disabilities, the separated, the uneducated, those with a very poor perceived health status and those with an economical burden for medical treatment was 19.3%, 18.9%, 19.0%, 19.3%, 19.0%, 20.2% and 24.3%, respectively. For subjects with surplus medicine, averages for the number of used pharmacies, the pharmacy-visit days and the medication costs were 4.6 drugstores, 34.9 days and approximately 1,124 thousand Won. These values were higher than those without surplus medicine (4.4 drugstores , 33.8 days, and 1,110 thousand won, respectively). The odds ratios of the contributing factors to surplus medicine were female 1.11 (95% CI=1.07-1.14), the elderly 1.06 (95% CI=1.02-1.10), those with non-disabilities 1.08 (95% CI=1.05-1.12), the separated 1.14 (95% CI=1.10-1.18), the unmarried 1.12 (95% CI=1.07-1.18), the uneducated 1.03 (95% CI=1.01-1.08), those with a very poor perceived health status 1.04 (95% CI=1.01-1.08) and experiencing an economical burden for medical treatment 2.33 (95% CI=2.26-2.40). CONCLUSIONS: 18.5% of subjects had surplus medicine with a higher mean of medication cost. Therefore, health education and health promotion programs to prevent surplus medicine and to improve the appropriate usage of medication are necessary.

A determination of topics for health technology assessment in Thailand: making decision makers involved.

This study is to describe experiences and findings from the topic selection process for health technology assessment (HTA) conducted by Health Intervention and Technology Assessment Program. The process comprised of 5 stages namely: (1) determining objectives, scope and involved stakeholders; (2) requesting potential topics for assessment from decision makers at the national health authorities; (3) reviewing related literature on and prioritizing the proposed HTA topics by HITAP researchers; (4) selecting the HTA topics by decisionmakers; (5) analyzing the strengths and weaknesses of the current topic selection processes by HITAP staff The strengths of the topic selection were systematic and transparent. It also required participation from stakeholders; however the limitations were topics prioritization methods and time constraints. Lessons learnt from this procedure can be useful for improving the next HTA topic selection in order to increase the usefulness of the future HTA results.